EQT Partners, a private equity firm, completed the acquisition of Mabtech, a specialist in immune monitoring, from IK Investment Partners, a Pan-European private equity firm. Financial terms were not disclosed. "This is a high-quality player with deep technical and scientific expertise in a growing niche market, that we have been following for many years. By offering 'must-haves' along the drug development value chain and building on its leading position in Europe, Mabtech is well-placed to expand its scale and reach, especially in the US. This is an ideal example of the kind of company that the EQT Healthcare Growth Strategy seeks to continue investing in: it's a fast-growing European champion with innovative, proven solutions that drive positive healthcare outcomes. We look forward to working with Jan Wahlström and team to help Mabtech reach its full growth potential," Isabel de Paoli, EQT Partners Partner.